KZR Kezar Life Sciences, Inc. Common Stock
XNAS
7.54
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $5.98 – $7.55
- YTD
- +19.87%
- IV Rank (30D)
- 3.6
- Straddle Price
- $0.35
- Market Cap
- $0.1B
- Open
- $7.36
- Day Range
- $7.27 – $7.47
- Volume
- 616,015
- Prev Close
- $7.36

- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 9
- List Date
- 2018-06-21
- CIK
- 0001645666
- Headquarters
- South San Francisco, CA
- Homepage
- https://www.kezarlifesciences.com
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL with confidence level 6/10
Key drivers: Recent news sentiment, options activity, and technical signals
Primary risks: Volatility fluctuations, potential for overbought conditions
Investment thesis: KZR's recent price action is influenced by a combination of factors. The stock's low volatility and bullish momentum indicators suggest a potentially stable short-term trend. However, the lack of recent news headlines and mixed technical signals reduce confidence in this assessment.
Recent news sentiment impact: With no recent news available, we cannot assess its impact on the stock price.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): NEUTRAL, Medium-term (1-3 months): BULLISH, Long-term (3-12 months): BEARISH
Support/Resistance Levels:
- Upper: $4.25
- Middle: $3.88
- Lower: $3.51
Momentum Signals: RSI interpretation: 59.94 (neutral) MACD signal: Bearish (0.06 / Signal: 0.06 / Histogram: -0.00) Bollinger Bands position: Neutral (middle band touching upper and lower bands)
Volume Analysis: Volume trends suggest low institutional interest, with a volume rate of change indicating decreasing activity.
News & Sentiment Analysis
Recent Headlines Summary: None available
Sentiment Assessment: Unable to assess sentiment without recent news headlines
Catalyst Identification: No upcoming events or announcements that could impact the stock price
Market Narrative: The lack of recent news headlines and mixed technical signals suggests a potentially neutral market narrative.
Risk & Volatility Assessment
Beta Interpretation: 0.80 (low volatility relative to SPY)
Volatility Regime: Low volatility regime, with average true range at $0.25
Options Market Signals:
- IV Rank: Medium (30.8%)
- Put/Call Volume Ratio: Bullish sentiment (2 calls vs 0 puts)
- Open Interest: Bullish bias (1 call vs 0 puts)
Market Context & Positioning
Sector Performance: Not applicable (no sector data available)
Institutional Activity: Low institutional interest, with decreasing volume trends
Correlation Analysis: KZR's price movement is less correlated to the market (R-squared interpretation: 0.31)
Relative Valuation: KZR's current price relative to its trading range suggests a potentially overbought condition.
Key Levels & Action Items
Critical Price Levels:
- Support: $3.51
- Resistance: $4.25
Breakout/Breakdown Levels: None identified
Time-Sensitive Catalysts: No upcoming events or announcements that could impact the stock price
Risk Management: Stop-loss levels should be set at the lower band ($3.51) to manage potential losses.
Note: This analysis provides a comprehensive view of KZR's current technical, news, and sentiment conditions. However, without recent news headlines, confidence in this assessment is reduced. Further analysis would be necessary with new information.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | After-Close | 1.36% | 0.89% | 0.65x | Within |
| 2021-11-09 | After-Close | 4.25% | 4.12% | 0.97x | Within |
| 2022-03-17 | After-Close | 0.59% | 1.83% | 3.10x | Exceeded |
| 2022-05-03 | After-Close | 4.91% | 43.51% | 8.86x | Exceeded |
| 2022-07-11 | After-Close | 0.55% | 1.00% | 1.82x | Exceeded |
| 2023-05-11 | After-Close | 9.82% | 0.77% | 0.08x | Within |
| 2023-11-13 | After-Close | 250.68% | 7.60% | 0.03x | Within |
| 2024-01-08 | After-Close | 160.15% | 0.55% | 0.00x | Within |
| 2024-03-14 | After-Close | 152.85% | 3.53% | 0.02x | Within |
| 2024-08-13 | After-Close | 279.13% | 5.05% | 0.02x | Within |
| 2024-11-12 | After-Close | 91.12% | 0.67% | 0.01x | Within |
| 2025-01-10 | After-Close | 105.22% | 3.23% | 0.03x | Within |
| 2025-03-25 | After-Close | 82.45% | 8.33% | 0.10x | Within |
| 2025-05-13 | After-Close | 47.02% | 1.67% | 0.04x | Within |
| 2025-08-13 | After-Close | 89.92% | 1.53% | 0.02x | Within |
| 2025-11-12 | After-Close | 25.97% | 0.16% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
KZR Options Activity & IV Rank
KZR IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow
ATM Options Pricing
Chain Summary
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Estimated net dealer gamma is at the 96th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
KZR Institutional Ownership (13F)
Latest filings — 2025-12-31Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
KZR Insider Trading (Form 4)
Latest: 2026-05-11| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Mark C. Schiller | Chief Operating Officer | U | −2,739 | — | EDGAR | |
| 2026-05-11 | Pichi Luo Chiang | SVP, Corporate Controller | U | −2,711 | — | EDGAR | |
| 2026-05-11 | Michael Kauffman | Director | U | −6,369 | — | EDGAR | |
| 2026-05-11 | Franklin M Berger | Director | U | −89,069 | — | EDGAR | |
| 2026-05-11 | Christopher J. Kirk | CEO | U | −43,134 | — | EDGAR | |
| 2026-05-11 | Marc Belsky | Chief Financial Officer | U | −1,738 | — | EDGAR | |
| 2026-05-11 | Graham K Cooper | Director | Disp (D) | −27,709 opt | — | EDGAR | |
| 2026-05-11 | Elizabeth Garner | Director | Disp (D) | −21,368 opt | — | EDGAR | |
| 2026-05-11 | Courtney Wallace | Director | Disp (D) | −21,300 opt | — | EDGAR | |
| 2026-05-11 | John Franklin Fowler | Director | U | −43,611 | — | EDGAR | |
| 2026-05-11 | Micki Klearman | Director | Disp (D) | −23,900 opt | — | EDGAR | |
| 2025-07-03 | Pichi Luo Chiang | SVP, Corporate Controller | Sell (S) | −264 | $4.28 | -$1.1K | EDGAR |
| 2025-07-03 | Mark C. Schiller | Chief Operating Officer | Sell (S) | −561 | $4.28 | -$2.4K | EDGAR |
| 2025-07-01 | Zung Phuong To | Chief Development Officer | Grant (A) | +7,000 opt | — | EDGAR | |
| 2025-06-23 | Franklin M Berger | Director | Grant (A) | +5,000 opt | — | EDGAR |
KZR Board & Officers
As of SEC filings through May 11, 2026Changes in the last 10 years (88)
| May 11, 2026 | Pichi Luo Chiang reported in an SEC filing no longer being SVP, Corporate Controller |
| May 11, 2026 | Micki Klearman reported in an SEC filing no longer being a director |
| May 11, 2026 | Michael Kauffman reported in an SEC filing no longer being a director |
| May 11, 2026 | Mark C. Schiller reported in an SEC filing no longer being Chief Legal Officer |
| May 11, 2026 | Marc Belsky reported in an SEC filing no longer being Chief Financial Officer |
| May 11, 2026 | John Franklin Fowler reported in an SEC filing no longer being a director |
| May 11, 2026 | Graham K Cooper reported in an SEC filing no longer being a director |
| May 11, 2026 | Franklin M Berger reported in an SEC filing no longer being a director |
| May 11, 2026 | Elizabeth Garner reported in an SEC filing no longer being a director |
| May 11, 2026 | Courtney Wallace reported in an SEC filing no longer being a director |
| May 11, 2026 | Christopher J. Kirk reported in an SEC filing no longer being a director |
| May 11, 2026 | Christopher J. Kirk reported in an SEC filing no longer being CEO |
| Apr 1, 2026 | The company announced the departure of Zung Phuong To as SVP, Clinical Development in an SEC filing |
| Apr 1, 2025 | Zung Phuong To became SVP, Clinical Development |
| Apr 1, 2025 | Pichi Luo Chiang became SVP, Corporate Controller |
| Jan 15, 2024 | Mark C. Schiller became Chief Legal Officer |
| Nov 9, 2023 | Christopher J. Kirk first listed as CEO in an SEC filing |
| Sep 30, 2023 | The company announced the departure of Noreen Henig as Chief Medical Officer in an SEC filing |
| Sep 30, 2023 | The company announced the departure of John Franklin Fowler as CEO in an SEC filing |
| Jul 24, 2023 | Christopher J. Kirk no longer listed as President and CSO in SEC filings |
| Jul 11, 2022 | Nicholas Michael Mordwinkin became Chief Business Officer |
| May 11, 2022 | The company announced the departure of Jean-Pierre Sommadossi from the board in an SEC filing |
| Dec 9, 2021 | The company announced the departure of Jason Dinges from the board in an SEC filing |
| Dec 9, 2021 | Courtney Wallace became a director |
| Jun 1, 2021 | Micki Klearman became a director |
| May 1, 2020 | Noreen Henig became Chief Medical Officer |
| Feb 4, 2020 | Equal Talent Investments Ltd became a 10% owner |
| Dec 18, 2019 | Elizabeth Garner became a director |
| Mar 4, 2019 | Vassiliki Economides became SVP, Strategy & External Aff. |
| Jul 5, 2018 | Thomas F Steyer reported in an SEC filing no longer being a 10% owner |
| Jun 28, 2018 | Bay City Capital LLC reported in an SEC filing no longer being a 10% owner |
| Jun 27, 2018 | Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner |
| Jun 27, 2018 | Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner |
| Jun 27, 2018 | Bihua Chen reported in an SEC filing no longer being a director |
| Jun 27, 2018 | Bihua Chen reported in an SEC filing no longer being a 10% owner |
| Jun 27, 2018 | Aberdare Management Company, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2018 | Pappas Capital, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2018 | PV V CEO Fund, LP reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2018 | Giacomo Chiesi reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2018 | Chiesi Ventures, LP reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2018 | Chiesi Ventures, Inc. reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2018 | Arthur M Pappas reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2018 | AMP&A Management V, LLC reported in an SEC filing no longer being a 10% owner |
| Jun 26, 2018 | A.M. Pappas Life Science Ventures V, LP reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2018 | Richard J. Lim reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2018 | Otello Stampacchia reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2018 | Onyx Therapeutics, Inc. reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2018 | Omega Fund IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2018 | Omega Fund IV GP, L.P. reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2018 | Omega Fund IV G.P. Manager, Ltd. reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2018 | Anne-Mari Paster reported in an SEC filing no longer being a 10% owner |
| Jun 25, 2018 | Amgen Inc reported in an SEC filing no longer being a 10% owner |
| Jun 20, 2018 | Thomas F Steyer became a 10% owner |
| Jun 20, 2018 | Richard J. Lim became a 10% owner |
| Jun 20, 2018 | Pappas Capital, LLC became a 10% owner |
| Jun 20, 2018 | PV V CEO Fund, LP became a 10% owner |
| Jun 20, 2018 | Otello Stampacchia became a 10% owner |
| Jun 20, 2018 | Onyx Therapeutics, Inc. became a 10% owner |
| Jun 20, 2018 | Omega Fund IV, L.P. became a 10% owner |
| Jun 20, 2018 | Omega Fund IV GP, L.P. became a 10% owner |
| Jun 20, 2018 | Omega Fund IV G.P. Manager, Ltd. became a 10% owner |
| Jun 20, 2018 | Niti Goel became Chief Medical Officer |
| Jun 20, 2018 | Morningside Venture Investments Ltd became a 10% owner |
| Jun 20, 2018 | Michael Kauffman became a director |
| Jun 20, 2018 | Marc Belsky became Chief Financial Officer |
| Jun 20, 2018 | John Franklin Fowler became a director |
| Jun 20, 2018 | John Franklin Fowler became CEO |
| Jun 20, 2018 | Jean-Pierre Sommadossi became a director |
| Jun 20, 2018 | Jason Dinges became a director |
| Jun 20, 2018 | Graham K Cooper became a director |
| Jun 20, 2018 | Giacomo Chiesi became a 10% owner |
| Jun 20, 2018 | Franklin M Berger became a director |
| Jun 20, 2018 | Cormorant Private Healthcare Fund I, LP became a 10% owner |
| Jun 20, 2018 | Cormorant Global Healthcare Master Fund, LP became a 10% owner |
| Jun 20, 2018 | Cormorant Asset Management, LP became a 10% owner |
| Jun 20, 2018 | Christopher J. Kirk became a director |
| Jun 20, 2018 | Christopher J. Kirk became President and CSO |
| Jun 20, 2018 | Chiesi Ventures, LP became a 10% owner |
| Jun 20, 2018 | Chiesi Ventures, Inc. became a 10% owner |
| Jun 20, 2018 | Bihua Chen became a director |
| Jun 20, 2018 | Bihua Chen became a 10% owner |
| Jun 20, 2018 | Bay City Capital LLC became a 10% owner |
| Jun 20, 2018 | Arthur M Pappas became a 10% owner |
| Jun 20, 2018 | Anne-Mari Paster became a 10% owner |
| Jun 20, 2018 | Amgen Inc became a 10% owner |
| Jun 20, 2018 | Aberdare Management Company, LLC became a 10% owner |
| Jun 20, 2018 | AMP&A Management V, LLC became a 10% owner |
| Jun 20, 2018 | A.M. Pappas Life Science Ventures V, LP became a 10% owner |
- Prev
- 1
- …
Not reported recently (6)
- Nicholas Michael Mordwinkin · Last reported as Chief Business Officer in an SEC filing dated Jan 9, 2024
- Morningside Venture Investments Ltd · Last reported as a 10% owner in an SEC filing dated Aug 17, 2023
- Vassiliki Economides · Last reported as SVP, Strategy & External Aff. in an SEC filing dated Mar 29, 2021
- Equal Talent Investments Ltd · Last reported as a 10% owner in an SEC filing dated Jun 15, 2020
- Niti Goel · Last reported as Chief Medical Officer in an SEC filing dated Jan 8, 2019
- Cormorant Private Healthcare Fund I, LP · Last reported as a 10% owner in an SEC filing dated Jun 20, 2018
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | — | $-5.76M | $-0.78 | $-7.45M |
| Q4 '25 | 2025-12-31 | — | $-14.55M | $-1.99 | $-11.96M |
| Q3 '25 | 2025-09-30 | — | $-11.23M | $-1.53 | $-9.83M |
| Q2 '25 | 2025-06-30 | — | $-13.70M | $-1.87 | $-12.79M |
| Q1 '25 | 2025-03-31 | — | $-16.56M | $-2.27 | $-17.19M |
| Q4 '24 | 2024-12-31 | — | $-20.22M | $-2.77 | $-16.82M |
| Q3 '24 | 2024-09-30 | — | $-20.31M | $-2.78 | $-17.49M |
| Q2 '24 | 2024-06-30 | — | $-21.55M | $-2.96 | $-17.03M |
| Q1 '24 | 2024-03-31 | — | $-21.66M | $-2.98 | $-22.86M |
| Q4 '23 | 2023-12-31 | $0.00 | $-32.26M | $-4.44 | $-18.98M |
| Q3 '23 | 2023-09-30 | $7.00M | $-23.10M | $-3.18 | $-20.20M |
| Q2 '23 | 2023-06-30 | — | $-24.31M | $-3.40 | $-21.60M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.